Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by Canaccord Genuity
Canaccord Genuity cut shares of Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Marketbeat.com reports.
Separately, HC Wainwright downgraded Inotek Pharmaceuticals Corporation from a buy rating to a neutral rating and set a $2.00 price target on the stock. in a research note on Tuesday, July 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Inotek Pharmaceuticals Corporation has an average rating of Hold and a consensus target price of $3.80.
Shares of Inotek Pharmaceuticals Corporation (NASDAQ ITEK) traded up 12.90% on Wednesday, hitting $1.05. The stock had a trading volume of 1,834,094 shares. The company’s market cap is $28.34 million. The firm’s 50-day moving average is $1.80 and its 200-day moving average is $2.27. Inotek Pharmaceuticals Corporation has a one year low of $0.85 and a one year high of $9.90.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.01. On average, analysts expect that Inotek Pharmaceuticals Corporation will post ($1.45) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by Canaccord Genuity” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/07/17/inotek-pharmaceuticals-corporation-nasdaqitek-downgraded-by-canaccord-genuity.html.
Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its stake in Inotek Pharmaceuticals Corporation by 276.0% in the first quarter. Goldman Sachs Group Inc. now owns 58,758 shares of the biotechnology company’s stock worth $118,000 after buying an additional 43,131 shares during the period. Minerva Advisors LLC acquired a new stake in Inotek Pharmaceuticals Corporation during the first quarter worth $126,000. Columbus Circle Investors increased its stake in Inotek Pharmaceuticals Corporation by 78.4% in the first quarter. Columbus Circle Investors now owns 385,229 shares of the biotechnology company’s stock worth $770,000 after buying an additional 169,262 shares during the period. Highbridge Capital Management LLC increased its stake in Inotek Pharmaceuticals Corporation by 183.2% in the fourth quarter. Highbridge Capital Management LLC now owns 90,947 shares of the biotechnology company’s stock worth $554,000 after buying an additional 58,828 shares during the period. Finally, Putnam Investments LLC increased its stake in Inotek Pharmaceuticals Corporation by 1.3% in the fourth quarter. Putnam Investments LLC now owns 34,520 shares of the biotechnology company’s stock worth $211,000 after buying an additional 447 shares during the period. Hedge funds and other institutional investors own 38.49% of the company’s stock.
Inotek Pharmaceuticals Corporation Company Profile
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.